Able 0 4 0 4 O
to 5 7 5 7 O
swallow 8 15 8 15 O
and 16 19 16 19 O
retain 20 26 20 26 O
oral 27 31 27 31 B-treatment
medication 32 42 32 42 I-treatment

Active 0 6 43 49 B-chronic_disease
hepatitis 7 16 50 59 I-chronic_disease
B 17 18 60 61 I-chronic_disease
infection 19 28 62 71 I-chronic_disease
, 28 29 71 72 O
active 30 36 73 79 B-chronic_disease
hepatitis 37 46 80 89 I-chronic_disease
C 47 48 90 91 I-chronic_disease
infection 49 58 92 101 I-chronic_disease

Additional 0 10 102 112 O
experimental 11 23 113 125 O
anti 24 28 126 130 B-treatment
- 28 29 130 131 I-treatment
cancer 29 35 131 137 I-treatment
treatment 36 45 138 147 I-treatment
and/or 46 52 148 154 O
standard 53 61 155 163 O
chemo- 62 68 164 170 O
, 68 69 170 171 O
immunotherapy 70 83 172 185 B-treatment
, 83 84 185 186 O
hormone 85 92 187 194 B-treatment
treatment 93 102 195 204 I-treatment
( 103 104 205 206 O
with 104 108 206 210 O
the 109 112 211 214 O
exception 113 122 215 224 O
of 123 125 225 227 O
megestrol 126 135 228 237 B-treatment
acetate 136 143 238 245 I-treatment
) 143 144 245 246 O
, 144 145 246 247 O
or 146 148 248 250 O
concurrent 149 159 251 261 B-treatment
radiotherapy 160 172 262 274 I-treatment
is 173 175 275 277 O
not 176 179 278 281 O
allowed 180 187 282 289 O
concomitantly 188 201 290 303 O
with 202 206 304 308 O
the 207 210 309 312 O
administration 211 225 313 327 O
of 226 228 328 330 O
study 229 234 331 336 O
treatment 235 244 337 346 O
( 245 246 347 348 O
with 246 250 348 352 O
the 251 254 353 356 O
exception 255 264 357 366 O
listed 265 271 367 373 O
in 272 274 374 376 O
section 275 282 377 384 O
9.0 283 286 385 388 O
) 286 287 388 389 O
89Zr 288 292 390 394 B-treatment
- 292 293 394 395 I-treatment
trastuzumab 293 304 395 406 I-treatment
use 305 308 407 410 O
as 309 311 411 413 O
imaging 312 319 414 421 O
agent 320 325 422 427 O
for 326 329 428 431 O
89Zr 330 334 432 436 O
- 334 335 436 437 O
trastuzumab 335 346 437 448 O
PET 347 350 449 452 B-clinical_variable
permitted 351 360 453 462 O
. 360 361 462 463 O
Afatinib 362 370 464 472 B-treatment
is 371 373 473 475 O
a 374 375 476 477 O
substrate 376 385 478 487 O
of 386 388 488 490 O
P 389 390 491 492 B-clinical_variable
- 390 391 492 493 I-clinical_variable
gp 391 393 493 495 I-clinical_variable
and 394 397 496 499 O
its 398 401 500 503 O
plasma 402 408 504 510 O
concentrations 409 423 511 525 O
can 424 427 526 529 O
be 428 430 530 532 O
affected 431 439 533 541 O
by 440 442 542 544 O
the 443 446 545 548 O
use 447 450 549 552 O
of 451 453 553 555 O
P 454 455 556 557 O
- 455 456 557 558 O
gp 456 458 558 560 O
inhibitors 459 469 561 571 O
( 470 471 572 573 O
data 471 475 573 577 O
on 476 478 578 580 O
file 479 483 581 585 O
) 483 484 585 586 O
and 485 488 587 590 O
it 489 491 591 593 O
is 492 494 594 596 O
also 495 499 597 601 O
likely 500 506 602 608 O
that 507 511 609 613 O
P 512 513 614 615 O
- 513 514 615 616 O
gp 514 516 616 618 O
inducers 517 525 619 627 O
could 526 531 628 633 O
also 532 536 634 638 O
influence 537 546 639 648 O
afatinib 547 555 649 657 B-treatment
plasma 556 562 658 664 I-treatment
concentrations 563 577 665 679 O

All 0 3 680 683 O
patients 4 12 684 692 O
with 13 17 693 697 O
disease 18 25 698 705 O
technically 26 37 706 717 O
amenable 38 46 718 726 O
to 47 49 727 729 O
biopsy 50 56 730 736 B-treatment
will 57 61 737 741 O
be 62 64 742 744 O
asked 65 70 745 750 O
to 71 73 751 753 O
undergo 74 81 754 761 O
a 82 83 762 763 O
biopsy 84 90 764 770 O
. 90 91 770 771 O
Patient 92 99 772 779 O
must 100 104 780 784 O
agree 105 110 785 790 O
to 111 113 791 793 O
allow 114 119 794 799 O
2 120 121 800 801 O
biopsies 122 130 802 810 B-treatment
of 131 133 811 813 O
any 134 137 814 817 O
malignant 138 147 818 827 B-cancer
lesion 148 154 828 834 I-cancer
that 155 159 835 839 O
can 160 163 840 843 O
be 164 166 844 846 O
accessed 167 175 847 855 O
by 176 178 856 858 O
endoscopy 179 188 859 868 B-treatment
or 189 191 869 871 O
with 192 196 872 876 O
the 197 200 877 880 O
aid 201 204 881 884 O
or 205 207 885 887 O
radiology 208 217 888 897 B-treatment
( 218 219 898 899 O
i.e. 219 223 899 903 O
CT 224 226 904 906 B-treatment
guided 227 233 907 913 O
) 233 234 913 914 O

Asymptomatic 0 12 915 927 O
, 12 13 927 928 O
central 14 21 929 936 B-cancer
nervous 22 29 937 944 I-cancer
system 30 36 945 951 I-cancer
metastases 37 47 952 962 I-cancer

At 0 2 963 965 O
least 3 8 966 971 O
one 9 12 972 975 B-lower_bound
measurable 13 23 976 986 O
metastatic 24 34 987 997 B-cancer
lesion 35 41 998 1004 I-cancer
according 42 51 1005 1014 O
to 52 54 1015 1017 O
RECIST 55 61 1018 1024 O
1.1 62 65 1025 1028 O
criteria 66 74 1029 1037 O
. 74 75 1037 1038 O
Ascites 76 83 1039 1046 B-chronic_disease
, 83 84 1046 1047 O
pleural 85 92 1048 1055 B-chronic_disease
effusions 93 102 1056 1065 I-chronic_disease
, 102 103 1065 1066 O
and 104 107 1067 1070 O
bone 108 112 1071 1075 B-cancer
metastases 113 123 1076 1086 I-cancer
are 124 127 1087 1090 O
not 128 131 1091 1094 O
considered 132 142 1095 1105 O
measurable 143 153 1106 1116 O
. 153 154 1116 1117 O
Minimum 155 162 1118 1125 O
indicator 163 172 1126 1135 O
lesion 173 179 1136 1142 B-clinical_variable
size 180 184 1143 1147 I-clinical_variable
= 185 186 1148 1149 O
10 187 189 1150 1152 B-lower_bound
mm 190 192 1153 1155 I-lower_bound
by 193 195 1156 1158 O
helical 196 203 1159 1166 B-treatment
CT 204 206 1167 1169 I-treatment
or 207 209 1170 1172 O
= 210 211 1173 1174 O
20 212 214 1175 1177 B-lower_bound
mm 215 217 1178 1180 I-lower_bound
by 218 220 1181 1183 O
conventional 221 233 1184 1196 O
techniques 234 244 1197 1207 O
. 244 245 1207 1208 O
Pathological 246 258 1209 1221 O
nodes 259 264 1222 1227 O
must 265 269 1228 1232 O
be 270 272 1233 1235 O
= 273 274 1236 1237 O
15 275 277 1238 1240 O
mm 278 280 1241 1243 O
by 281 283 1244 1246 O
the 284 287 1247 1250 O
short 288 293 1251 1256 O
axis 294 298 1257 1261 O
to 299 301 1262 1264 O
be 302 304 1265 1267 O
considered 305 315 1268 1278 O
measurable 316 326 1279 1289 O

Baseline 0 8 1290 1298 O
( 9 10 1299 1300 O
< 10 11 1300 1301 O
1 12 13 1302 1303 B-upper_bound
month 14 19 1304 1309 I-upper_bound
before 20 26 1310 1316 I-upper_bound
treatment 27 36 1317 1326 B-treatment
) 36 37 1326 1327 O
cardiac 38 45 1328 1335 B-clinical_variable
left 46 50 1336 1340 I-clinical_variable
ventricular 51 62 1341 1352 I-clinical_variable
function 63 71 1353 1361 I-clinical_variable
with 72 76 1362 1366 O
resting 77 84 1367 1374 B-clinical_variable
ejection 85 93 1375 1383 I-clinical_variable
fraction 94 102 1384 1392 I-clinical_variable
of 103 105 1393 1395 O
less 106 110 1396 1400 O
than 111 115 1401 1405 O
50 116 118 1406 1408 B-upper_bound
% 118 119 1408 1409 I-upper_bound
measured 120 128 1410 1418 O
by 129 131 1419 1421 O
echocardiogram 132 146 1422 1436 B-treatment

Completion 0 10 1437 1447 O
of 11 13 1448 1450 O
previous 14 22 1451 1459 B-treatment
chemotherapy 23 35 1460 1472 I-treatment
regimen 36 43 1473 1480 I-treatment
â‰¥2 44 46 1481 1483 O
weeks 47 52 1484 1489 I-lower_bound
prior 53 58 1490 1495 I-lower_bound
to 59 61 1496 1498 O
the 62 65 1499 1502 O
start 66 71 1503 1508 O
of 72 74 1509 1511 O
study 75 80 1512 1517 B-treatment
treatment 81 90 1518 1527 I-treatment
. 90 91 1527 1528 O
Other 92 97 1529 1534 O
chemotherapy 98 110 1535 1547 O
regimens 111 119 1548 1556 O
may 120 123 1557 1560 O
have 124 128 1561 1565 O
been 129 133 1566 1570 O
administered 134 146 1571 1583 O
between 147 154 1584 1591 O
the 155 158 1592 1595 O
time 159 163 1596 1600 O
of 164 166 1601 1603 O
progression 167 178 1604 1615 O
on 179 181 1616 1618 O
prior 182 187 1619 1624 O
trastuzumab 188 199 1625 1636 B-treatment
containing 200 210 1637 1647 O
regimen 211 218 1648 1655 O
and 219 222 1656 1659 O
protocol 223 231 1660 1668 B-treatment
therapy 232 239 1669 1676 I-treatment
. 239 240 1676 1677 O
No 241 243 1678 1680 O
restriction 244 255 1681 1692 O
on 256 258 1693 1695 O
prior 259 264 1696 1701 B-treatment
chemotherapy 265 277 1702 1714 I-treatment
regimens 278 286 1715 1723 O
for 287 290 1724 1727 O
advanced 291 299 1728 1736 B-chronic_disease
stage 300 305 1737 1742 I-chronic_disease
disease 306 313 1743 1750 I-chronic_disease

Concurrent 0 10 1751 1761 O
medical 11 18 1762 1769 B-chronic_disease
conditions 19 29 1770 1780 I-chronic_disease
which 30 35 1781 1786 O
may 36 39 1787 1790 O
increase 40 48 1791 1799 O
the 49 52 1800 1803 O
risk 53 57 1804 1808 O
of 58 60 1809 1811 O
toxicity 61 69 1812 1820 O
, 69 70 1820 1821 O
including 71 80 1822 1831 O
ongoing 81 88 1832 1839 O
or 89 91 1840 1842 O
active 92 98 1843 1849 B-chronic_disease
infection 99 108 1850 1859 I-chronic_disease
, 108 109 1859 1860 O
history 110 117 1861 1868 O
of 118 120 1869 1871 O
significant 121 132 1872 1883 O
bleeding 133 141 1884 1892 B-chronic_disease
disorder 142 150 1893 1901 I-chronic_disease
unrelated 151 160 1902 1911 O
to 161 163 1912 1914 O
cancer 164 170 1915 1921 B-cancer
( 171 172 1922 1923 O
congenital 172 182 1923 1933 B-chronic_disease
bleeding 183 191 1934 1942 I-chronic_disease
disorders 192 201 1943 1952 I-chronic_disease
, 201 202 1952 1953 O
acquired 203 211 1954 1962 O
bleeding 212 220 1963 1971 O
disorders 221 230 1972 1981 O
within 231 237 1982 1988 O
one 238 241 1989 1992 B-upper_bound
year 242 246 1993 1997 I-upper_bound
) 246 247 1997 1998 O
, 247 248 1998 1999 O
HIV 249 252 2000 2003 B-chronic_disease
- 252 253 2003 2004 O
positive 253 261 2004 2012 O

Concurrent 0 10 2013 2023 B-treatment
radiotherapy 11 23 2024 2036 I-treatment
is 24 26 2037 2039 O
not 27 30 2040 2043 O
permitted 31 40 2044 2053 O
for 41 44 2054 2057 O
disease 45 52 2058 2065 O
progression 53 64 2066 2077 O
on 65 67 2078 2080 O
treatment 68 77 2081 2090 B-treatment
on 78 80 2091 2093 O
protocol 81 89 2094 2102 O
( 90 91 2103 2104 O
except 91 97 2104 2110 O
in 98 100 2111 2113 O
the 101 104 2114 2117 O
context 105 112 2118 2125 O
specified 113 122 2126 2135 O
in 123 125 2136 2138 O
section 126 133 2139 2146 O
9.0 134 137 2147 2150 O
) 137 138 2150 2151 O
, 138 139 2151 2152 O
but 140 143 2153 2156 O
might 144 149 2157 2162 O
be 150 152 2163 2165 O
allowed 153 160 2166 2173 O
for 161 164 2174 2177 O
pre 165 168 2178 2181 O
- 168 169 2181 2182 O
existing 169 177 2182 2190 O
non 178 181 2191 2194 O
- 181 182 2194 2195 O
target 182 188 2195 2201 O
lesions 189 196 2202 2209 B-chronic_disease

Consent 0 7 2210 2217 O
to 8 10 2218 2220 O
preservation 11 23 2221 2233 O
of 24 26 2234 2236 O
frozen 27 33 2237 2243 O
and 34 37 2244 2247 O
fixed 38 43 2248 2253 O
samples 44 51 2254 2261 O
of 52 54 2262 2264 O
tumor 55 60 2265 2270 B-cancer
cores 61 66 2271 2276 O
for 67 70 2277 2280 O
evaluation 71 81 2281 2291 O

HER2 0 4 2292 2296 O
overexpression 5 19 2297 2311 O
and/or 20 26 2312 2318 O
amplification 27 40 2319 2332 O
as 41 43 2333 2335 O
determined 44 54 2336 2346 O
by 55 57 2347 2349 O
immunohistochemistry 58 78 2350 2370 B-treatment
( 79 80 2371 2372 O
3 80 81 2372 2373 O
+ 81 82 2373 2374 O
) 82 83 2374 2375 O
or 84 86 2376 2378 O
FISH 87 91 2379 2383 B-clinical_variable
( 92 93 2384 2385 O
â‰¥2.0 93 97 2385 2389 O
) 97 98 2389 2390 O

History 0 7 2391 2398 O
or 8 10 2399 2401 O
presence 11 19 2402 2410 O
of 20 22 2411 2413 O
clinically 23 33 2414 2424 O
relevant 34 42 2425 2433 O
cardiovascular 43 57 2434 2448 B-chronic_disease
abnormalities 58 71 2449 2462 I-chronic_disease
such 72 76 2463 2467 O
as 77 79 2468 2470 O
uncontrolled 80 92 2471 2483 B-chronic_disease
hypertension 93 105 2484 2496 I-chronic_disease
, 105 106 2496 2497 O
congestive 107 117 2498 2508 B-chronic_disease
heart 118 123 2509 2514 I-chronic_disease
failure 124 131 2515 2522 I-chronic_disease
NYHA 132 136 2523 2527 B-clinical_variable
classification 137 151 2528 2542 O
of 152 154 2543 2545 O
3 155 156 2546 2547 O
, 156 157 2547 2548 O
unstable 158 166 2549 2557 B-chronic_disease
angina 167 173 2558 2564 I-chronic_disease
or 174 176 2565 2567 O
poorly 177 183 2568 2574 O
controlled 184 194 2575 2585 O
arrhythmia 195 205 2586 2596 B-chronic_disease
. 205 206 2596 2597 O
Myocardial 207 217 2598 2608 B-chronic_disease
infarction 218 228 2609 2619 I-chronic_disease
within 229 235 2620 2626 O
6 236 237 2627 2628 B-upper_bound
months 238 244 2629 2635 I-upper_bound
prior 245 250 2636 2641 I-upper_bound
to 251 253 2642 2644 O
study 254 259 2645 2650 O
entry 260 265 2651 2656 O

Karnofsky 0 9 2657 2666 B-clinical_variable
performance 10 21 2667 2678 I-clinical_variable
status 22 28 2679 2685 I-clinical_variable
â‰¥60 29 32 2686 2689 O
% 32 33 2689 2690 I-lower_bound

Known 0 5 2691 2696 O
HIV 6 9 2697 2700 B-chronic_disease
carrier 10 17 2701 2708 O

Known 0 5 2709 2714 O
or 6 8 2715 2717 O
suspected 9 18 2718 2727 O
active 19 25 2728 2734 O
drug 26 30 2735 2739 O
or 31 33 2740 2742 O
alcohol 34 41 2743 2750 O
abuse 42 47 2751 2756 O
. 47 48 2756 2757 O
Restricted 49 59 2758 2768 O
Therapies 60 69 2769 2778 B-treatment

Known 0 5 2779 2784 O
pre 6 9 2785 2788 O
- 9 10 2788 2789 O
existing 10 18 2789 2797 O
interstitial 19 31 2798 2810 B-chronic_disease
lung 32 36 2811 2815 I-chronic_disease
disease 37 44 2816 2823 I-chronic_disease

Life 0 4 2824 2828 B-clinical_variable
expectancy 5 15 2829 2839 I-clinical_variable
of 16 18 2840 2842 O
at 19 21 2843 2845 O
least 22 27 2846 2851 O
three 28 33 2852 2857 B-lower_bound
( 34 35 2858 2859 I-lower_bound
3 35 36 2859 2860 I-lower_bound
) 36 37 2860 2861 I-lower_bound
months 38 44 2862 2868 I-lower_bound

May 0 3 2869 2872 O
have 4 8 2873 2877 O
previously 9 19 2878 2888 O
received 20 28 2889 2897 O
lapatinib 29 38 2898 2907 B-treatment
as 39 41 2908 2910 O
part 42 46 2911 2915 O
of 47 49 2916 2918 O
a 50 51 2919 2920 O
regimen 52 59 2921 2928 O
in 60 62 2929 2931 O
the 63 66 2932 2935 O
perioperative 67 80 2936 2949 O
or 81 83 2950 2952 O
metastatic 84 94 2953 2963 O
setting 95 102 2964 2971 O
with 103 107 2972 2976 O
evidence 108 116 2977 2985 O
of 117 119 2986 2988 O
progression 120 131 2989 3000 O
of 132 134 3001 3003 O
disease 135 142 3004 3011 O
. 142 143 3011 3012 O
Washout 144 151 3013 3020 O
period 152 158 3021 3027 O
for 159 162 3028 3031 O
lapatinib 163 172 3032 3041 O
of 173 175 3042 3044 O
14 176 178 3045 3047 B-upper_bound
days 179 183 3048 3052 I-upper_bound

Negative 0 8 3053 3061 B-pregnancy
serum 9 14 3062 3067 I-pregnancy
HCG 15 18 3068 3071 I-pregnancy
pregnancy 19 28 3072 3081 I-pregnancy
test 29 33 3082 3086 O
for 34 37 3087 3090 O
premenopausal 38 51 3091 3104 O
women 52 57 3105 3110 B-gender
of 58 60 3111 3113 O
reproductive 61 73 3114 3126 O
capacity 74 82 3127 3135 O
and 83 86 3136 3139 O
for 87 90 3140 3143 O
women 91 96 3144 3149 O
less 97 101 3150 3154 O
than 102 106 3155 3159 O
12 107 109 3160 3162 B-upper_bound
months 110 116 3163 3169 I-upper_bound
after 117 122 3170 3175 O
menopause 123 132 3176 3185 O

Pathologically 0 14 3186 3200 O
or 15 17 3201 3203 O
cytologically 18 31 3204 3217 O
confirmed 32 41 3218 3227 O
esophagogastric 42 57 3228 3243 B-cancer
cancer 58 64 3244 3250 I-cancer

Patients 0 8 3251 3259 O
aged 9 13 3260 3264 B-age
18 14 16 3265 3267 O
years 17 22 3268 3273 O
or 23 25 3274 3276 O
older 26 31 3277 3282 O
, 31 32 3282 3283 O
as 33 35 3284 3286 O
no 36 38 3287 3289 O
dosing 39 45 3290 3296 O
or 46 48 3297 3299 O
adverse 49 56 3300 3307 O
event 57 62 3308 3313 O
data 63 67 3314 3318 O
are 68 71 3319 3322 O
currently 72 81 3323 3332 O
available 82 91 3333 3342 O
on 92 94 3343 3345 O
the 95 98 3346 3349 O
use 99 102 3350 3353 O
of 103 105 3354 3356 O
afatinib 106 114 3357 3365 B-treatment
in 115 117 3366 3368 O
patients 118 126 3369 3377 O
< 127 128 3378 3379 O
18 128 130 3379 3381 O
years 131 136 3382 3387 O
of 137 139 3388 3390 O
age 140 143 3391 3394 O

Patients 0 8 3395 3403 O
receiving 9 18 3404 3413 O
any 19 22 3414 3417 O
concurrent 23 33 3418 3428 O
anticancer 34 44 3429 3439 B-treatment
therapy 45 52 3440 3447 I-treatment
or 53 55 3448 3450 O
investigational 56 71 3451 3466 B-treatment
agents 72 78 3467 3473 I-treatment
with 79 83 3474 3478 O
the 84 87 3479 3482 O
intention 88 97 3483 3492 O
of 98 100 3493 3495 O
treating 101 109 3496 3504 O
esophagogastric 110 125 3505 3520 B-cancer
cancer 126 132 3521 3527 I-cancer
. 132 133 3527 3528 O
89Zr 134 138 3529 3533 B-treatment
- 138 139 3533 3534 I-treatment
trastuzumab 139 150 3534 3545 I-treatment
uses 151 155 3546 3550 O
as 156 158 3551 3553 O
imaging 159 166 3554 3561 O
agent 167 172 3562 3567 O
for 173 176 3568 3571 O
89Zr 177 181 3572 3576 O
- 181 182 3576 3577 O
trastuzumab 182 193 3577 3588 O
PET 194 197 3589 3592 B-treatment
permitted 198 207 3593 3602 O

Patients 0 8 3603 3611 O
who 9 12 3612 3615 O
are 13 16 3616 3619 O
unwilling 17 26 3620 3629 O
to 27 29 3630 3632 O
consent 30 37 3633 3640 O
to 38 40 3641 3643 O
mandatory 41 50 3644 3653 O
tumor 51 56 3654 3659 B-treatment
biopsy 57 63 3660 3666 I-treatment
. 63 64 3666 3667 O
Patients 65 73 3668 3676 O
with 74 78 3677 3681 O
archival 79 87 3682 3690 O
tissue 88 94 3691 3697 O
permitted 95 104 3698 3707 O
to 105 107 3708 3710 O
enroll 108 114 3711 3717 O
on 115 117 3718 3720 O
study 118 123 3721 3726 O
per 124 127 3727 3730 O
MSK 128 131 3731 3734 O
Principal 132 141 3735 3744 O
Investigator 142 154 3745 3757 O
discretion 155 165 3758 3768 O
Women 166 171 3769 3774 B-gender
who 172 175 3775 3778 O
are 176 179 3779 3782 B-pregnancy
pregnant 180 188 3783 3791 I-pregnancy
or 189 191 3792 3794 O
breast 192 198 3795 3801 O
feeding 199 206 3802 3809 O

Patients 0 8 3810 3818 O
who 9 12 3819 3822 O
have 13 17 3823 3827 O
previously 18 28 3828 3838 O
provided 29 37 3839 3847 O
samples 38 45 3848 3855 O
at 46 48 3856 3858 O
any 49 52 3859 3862 O
time 53 57 3863 3867 O
after 58 63 3868 3873 O
trastuzumab 64 75 3874 3885 B-treatment
resistance 76 86 3886 3896 O
will 87 91 3897 3901 O
be 92 94 3902 3904 O
exempt 95 101 3905 3911 O
from 102 106 3912 3916 O
biopsy 107 113 3917 3923 B-treatment
at 114 116 3924 3926 O
the 117 120 3927 3930 O
start 121 126 3931 3936 O
of 127 129 3937 3939 O
therapy 130 137 3940 3947 B-treatment

Previously 0 10 3948 3958 O
received 11 19 3959 3967 O
trastuzumab 20 31 3968 3979 B-treatment
as 32 34 3980 3982 O
part 35 39 3983 3987 O
of 40 42 3988 3990 O
a 43 44 3991 3992 O
regimen 45 52 3993 4000 O
in 53 55 4001 4003 O
the 56 59 4004 4007 O
perioperative 60 73 4008 4021 O
or 74 76 4022 4024 O
metastatic 77 87 4025 4035 B-cancer
setting 88 95 4036 4043 O
with 96 100 4044 4048 O
evidence 101 109 4049 4057 O
of 110 112 4058 4060 O
progression 113 124 4061 4072 O
9Zr 125 128 4073 4076 B-treatment
- 128 129 4076 4077 I-treatment
trastuzumab 129 140 4077 4088 I-treatment
use 141 144 4089 4092 O
as 145 147 4093 4095 O
imaging 148 155 4096 4103 O
agent 156 161 4104 4109 O
for 162 165 4110 4113 O
89Zr 166 170 4114 4118 B-treatment
- 170 171 4118 4119 I-treatment
trastuzumab 171 182 4119 4130 I-treatment
PET 183 186 4131 4134 O
permitted 187 196 4135 4144 O

Prior 0 5 4145 4150 O
disease 6 13 4151 4158 O
progression 14 25 4159 4170 O
on 26 28 4171 4173 O
docetaxel 29 38 4174 4183 B-treatment
or 39 41 4184 4186 O
paclitaxel 42 52 4187 4197 B-treatment
in 53 55 4198 4200 O
metastatic 56 66 4201 4211 B-treatment
setting 67 74 4212 4219 I-treatment

Significant 0 11 4220 4231 O
or 12 14 4232 4234 O
recent 15 21 4235 4241 O
acute 22 27 4242 4247 B-chronic_disease
gastrointestinal 28 44 4248 4264 I-chronic_disease
disorders 45 54 4265 4274 I-chronic_disease
with 55 59 4275 4279 O
diarrhea 60 68 4280 4288 B-chronic_disease
as 69 71 4289 4291 O
a 72 73 4292 4293 O
major 74 79 4294 4299 O
symptom 80 87 4300 4307 O
e.g. 88 92 4308 4312 O
, 92 93 4312 4313 O
Crohn 94 99 4314 4319 B-chronic_disease
's 99 101 4319 4321 I-chronic_disease
disease 102 109 4322 4329 I-chronic_disease
, 109 110 4329 4330 O
malabsorption 111 124 4331 4344 B-chronic_disease
, 124 125 4344 4345 O
or 126 128 4346 4348 O
CTCAEGrade 129 139 4349 4359 B-clinical_variable
> 140 141 4360 4361 O
2 141 142 4361 4362 B-lower_bound
diarrhea 143 151 4363 4371 O
of 152 154 4372 4374 O
any 155 158 4375 4378 O
etiology 159 167 4379 4387 O

The 0 3 4388 4391 O
use 4 7 4392 4395 O
of 8 10 4396 4398 O
potent 11 17 4399 4405 O
P 18 19 4406 4407 B-treatment
- 19 20 4407 4408 I-treatment
gp 20 22 4408 4410 I-treatment
inhibitors 23 33 4411 4421 I-treatment
( 34 35 4422 4423 O
including 35 44 4423 4432 O
cyclosporine 45 57 4433 4445 B-treatment
, 57 58 4445 4446 O
erythromycin 59 71 4447 4459 B-treatment
, 71 72 4459 4460 O
ketoconazole 73 85 4461 4473 B-treatment
, 85 86 4473 4474 O
itraconazole 87 99 4475 4487 B-treatment
, 99 100 4487 4488 O
quinidine 101 110 4489 4498 B-treatment
, 110 111 4498 4499 O
Phenobarbital 112 125 4500 4513 B-treatment
salt 126 130 4514 4518 I-treatment
with 131 135 4519 4523 I-treatment
quinidine 136 145 4524 4533 I-treatment
, 145 146 4533 4534 O
ritonavir 147 156 4535 4544 B-treatment
, 156 157 4544 4545 O
valspodar 158 167 4546 4555 B-treatment
, 167 168 4555 4556 O
verapamil 169 178 4557 4566 B-treatment
) 178 179 4566 4567 O
and 180 183 4568 4571 O
potent 184 190 4572 4578 O
P 191 192 4579 4580 B-treatment
- 192 193 4580 4581 I-treatment
gp 193 195 4581 4583 I-treatment
inducers 196 204 4584 4592 I-treatment
( 205 206 4593 4594 O
including 206 215 4594 4603 O
St 216 218 4604 4606 B-treatment
John 219 223 4607 4611 I-treatment
's 223 225 4611 4613 I-treatment
wort 226 230 4614 4618 I-treatment
, 230 231 4618 4619 O
rifampicin 232 242 4620 4630 B-treatment
) 242 243 4630 4631 O
has 244 247 4632 4635 O
to 248 250 4636 4638 O
be 251 253 4639 4641 O
avoided 254 261 4642 4649 O
during 262 268 4650 4656 O
treatment 269 278 4657 4666 B-treatment
with 279 283 4667 4671 I-treatment
afatinib 284 292 4672 4680 I-treatment

Willingness 0 11 4681 4692 B-contraception_consent
to 12 14 4693 4695 I-contraception_consent
use 15 18 4696 4699 I-contraception_consent
birth 19 24 4700 4705 I-contraception_consent
control 25 32 4706 4713 I-contraception_consent
while 33 38 4714 4719 O
on 39 41 4720 4722 O
study 42 47 4723 4728 O

